Market Overview

UPDATE: Goldman Sachs Raises PT to $33 on Mylan on Agila Specialties Purchase

Share:
Related MYL
Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket
Challenge of two Lantus patents commences (Seeking Alpha)

In a report published Thursday, Goldman Sachs reiterated its Buy rating on Mylan (NYSE: MYL) and raised its price target from $32 to $33.

Goldman Sachs reported that, “MYL announced a definitive agreement to purchase Agila Specialties, a generics injectable producer from Strides Arcolab, for $1.6 bn in cash (+$250mn potential payments; expected to close 4Q13). We update estimates on the back of a strong quarter, higher than consensus guidance (even with higher R&D), and strong growth in specialty (30% yoy), but do not include this proposed deal. Longer term on top of possible synergies, we see prospects brightening with potential for generic Advair, where MYL is very well positioned. Management reiterated its $6.00 EPS target for 2018."

Mylan shares closed at $28.57 on Wednesday.

Latest Ratings for MYL

DateFirmActionFromTo
Dec 2017GuggenheimInitiates Coverage OnBuy
Oct 2017Morgan StanleyMaintainsEqual-Weight
Oct 2017BTIG ResearchMaintainsBuy

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYL)

View Comments and Join the Discussion!

Partner Center